Northwire Canada EditionTuesday, August 11, 2026
Northwire
OMI 0.270 −5.3% CUEX 0.090 +5.9% RAK 0.170 −2.9% TGOL 0.140 +12.0% DEC 0.085 +0.0% NWST 0.285 +0.0% CDA 0.900 +5.9% AVL 5.10 +1.0% FSY 0.570 +0.0% GTC 0.790 +11.3% FCI 0.460 +4.5% IDEX 0.370 +7.2% MERG 0.880 +6.0% CNL 19.86 +0.4% ALGR 0.620 −4.6% MEK 0.050 +0.0% OMI 0.270 −5.3% CUEX 0.090 +5.9% RAK 0.170 −2.9% TGOL 0.140 +12.0% DEC 0.085 +0.0% NWST 0.285 +0.0% CDA 0.900 +5.9% AVL 5.10 +1.0% FSY 0.570 +0.0% GTC 0.790 +11.3% FCI 0.460 +4.5% IDEX 0.370 +7.2% MERG 0.880 +6.0% CNL 19.86 +0.4% ALGR 0.620 −4.6% MEK 0.050 +0.0%
Financings

First Phosphate Closes Follow-on Tranche of Oversubscribed Private Placement

PHOS · Price

Executive Summary

  • First Phosphate Corp. closed a subsequent tranche of its non‑brokered private placement, raising $1,390,699 from the issuance of 1,111,110 Flow‑Through Shares and 431,111 Hard Dollar Units (including common shares and warrants).
  • Cumulatively, the company has now raised approximately $43.6 million across ten management‑led non‑brokered private placements since June 2022.
  • The Company also granted 4.7 million incentive stock options and 1.303 million restricted stock units to officers, directors and eligible participants under its Omnibus Equity Incentive Plan.

Key Details

  • Tranche 2 Financing (Nov 21 2025):
  • Flow‑Through Shares: 1,111,110 shares at a deemed price of $0.90 per share → $999,999 gross proceeds.
  • Hard Dollar Units: 431,111 units consisting of:
    • 431,111 common shares (price $0.90) → $390,700 gross proceeds.
    • 431,111 warrants exercisable at $1.25 per share (expiry Apr 30 2026, accelerated expiry date).
  • Total Raised in Tranche 2: $1,390,699.

  • Overall Offering Summary (both tranches):

  • Flow‑Through Shares: 3,355,832 shares → $3,020,249 gross proceeds.
  • Hard Dollar Units: 611,777 units → $550,560 gross proceeds.
  • Combined Gross Proceeds (both tranches): $3,570,848.

  • Cumulative Private‑Placement Funding Since June 2022: Approximately $43.6 million across ten management‑led financings.

  • Compensation Shares & Warrants Issued with Tranche 2:

  • 88,888 compensation common shares at $0.90 per share.
  • 88,888 compensation warrants exercisable at $1.25 per share (expiry Apr 30 2026, accelerated expiry date).

  • Corporate Finance Fee Paid: $12,500.

  • Statutory Hold Period: All securities issued are subject to a four‑month plus one‑day hold period under applicable securities laws.

  • Use of Proceeds: As disclosed in the Company’s November 7 2025 press release (intended for project development, working capital, and general corporate purposes).

  • Equity Incentive Grants (RSU & Options):

  • Incentive Stock Options: 4,700,000 options at $0.90 exercise price; expire Dec 29 2028; vest 25 % every six months over two years from grant date.
  • Restricted Stock Units: 1,303,000 RSUs; vest on Jan 1 2026.
  • All option and RSU securities also subject to the four‑month plus one‑day statutory hold period.

  • Future Financing Flexibility: Company may close additional tranches of the Offering at its discretion.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from First Phosphate Corp.